Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: Wiener Medizinische Wochenschrift 23-24/2015

01.12.2015 | review

Subantimicrobial-dose doxycycline monohydrate in dermatology

verfasst von: Prof. Dr. Uwe Wollina

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 23-24/2015

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

Subantimicrobial doxycycline is an anti-inflammatory drug that decreases cathelicidin, kallikrein 5, reactive oxygen species, nitric oxide, and matrix metalloproteinases. Clinical trials demonstrated a comparable efficacy to 100-mg doxycycline in papulopustular rosacea with improvement of inflammatory lesions, quality of life, and improved safety profile. Case series and case reports suggested efficacy in other inflammatory skin diseases. The response of papulopustular rash during targeted anticancer therapies is mixed. Further studies are needed.
Literatur
1.
Zurück zum Zitat Griffin MO, Ceballos G, Villarreal FJ. Tetracycline compounds with non-antimicrobial organ protective properties: possible mechanisms of action. Pharmacol Res. 2011;63:102–7. PubMedCentralCrossRefPubMed Griffin MO, Ceballos G, Villarreal FJ. Tetracycline compounds with non-antimicrobial organ protective properties: possible mechanisms of action. Pharmacol Res. 2011;63:102–7. PubMedCentralCrossRefPubMed
2.
Zurück zum Zitat Sloan B, Scheinfeld N. The use and safety of doxycycline hyclate and other second-generation tetracyclines. Expert Opin Drug Saf. 2008;7:571–7. CrossRefPubMed Sloan B, Scheinfeld N. The use and safety of doxycycline hyclate and other second-generation tetracyclines. Expert Opin Drug Saf. 2008;7:571–7. CrossRefPubMed
3.
Zurück zum Zitat Di Caprio R, Lembo S, Di Constanzo L, Balato A, Monfrecola G. Anti-inflammatory properties of low and high doxycycline doses: an in vitro study. Mediators Inflamm. 2015;2015:329418. PubMedCentralCrossRefPubMed Di Caprio R, Lembo S, Di Constanzo L, Balato A, Monfrecola G. Anti-inflammatory properties of low and high doxycycline doses: an in vitro study. Mediators Inflamm. 2015;2015:329418. PubMedCentralCrossRefPubMed
4.
Zurück zum Zitat Thomas J, Walker C, Bradshaw M. Long-term use of subantimicrobial dose doxycycline does not lead to changes in antimicrobial susceptibility. J Perdontol. 2000;71:1472–83. CrossRef Thomas J, Walker C, Bradshaw M. Long-term use of subantimicrobial dose doxycycline does not lead to changes in antimicrobial susceptibility. J Perdontol. 2000;71:1472–83. CrossRef
5.
Zurück zum Zitat Del Rosso JQ. A status report on the use of subantimicrobial-dose doxycycline: a review of the biologic and antimicrobial effect of the tetracyclines. Cutis. 2004;74:118–22. PubMed Del Rosso JQ. A status report on the use of subantimicrobial-dose doxycycline: a review of the biologic and antimicrobial effect of the tetracyclines. Cutis. 2004;74:118–22. PubMed
6.
Zurück zum Zitat Berman B, Perez OA, Zell D. Update on rosacea and anti-inflammatory-dose doxycycline. Drugs Today (Barc). 2007;43:27–34. CrossRef Berman B, Perez OA, Zell D. Update on rosacea and anti-inflammatory-dose doxycycline. Drugs Today (Barc). 2007;43:27–34. CrossRef
7.
Zurück zum Zitat Kanada KN, Nakatsuji T, Gallo RL. Doxycycline indirectly inhibits proteolytic activation of tryptic kallikrein-related peptidases and activation of cathelicidin. J Invest Dermatol. 2012;132:1435–42. PubMedCentralCrossRefPubMed Kanada KN, Nakatsuji T, Gallo RL. Doxycycline indirectly inhibits proteolytic activation of tryptic kallikrein-related peptidases and activation of cathelicidin. J Invest Dermatol. 2012;132:1435–42. PubMedCentralCrossRefPubMed
9.
Zurück zum Zitat Del Rosso JQ, Webster GF, Jackson M, et al. Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. J Am Acad Dermatol. 2007;56:791–802. CrossRefPubMed Del Rosso JQ, Webster GF, Jackson M, et al. Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. J Am Acad Dermatol. 2007;56:791–802. CrossRefPubMed
10.
Zurück zum Zitat Del Rosso JQ. Effectiveness and safety of doxycycline 40 mg (30-mg immediate-release and 10-mg delayed-release beads) once daily as add-on therapy to existing topical regimens for the treatment of papulopustular rosacea: results from a community-based trial. Cutis. 2010;86(5 Suppl.):16–25. PubMed Del Rosso JQ. Effectiveness and safety of doxycycline 40 mg (30-mg immediate-release and 10-mg delayed-release beads) once daily as add-on therapy to existing topical regimens for the treatment of papulopustular rosacea: results from a community-based trial. Cutis. 2010;86(5 Suppl.):16–25. PubMed
11.
Zurück zum Zitat Del Rosso JQ, Preston NJ, Caveney SW, Gottschalk RW. Effectiveness and safety of modified-release doxycycline capsules once daily for papulopustular rosacea monotherapy results from a large community-based trial in subgroups based on gender. J Drugs Dermatol. 2012;11:703–7. PubMed Del Rosso JQ, Preston NJ, Caveney SW, Gottschalk RW. Effectiveness and safety of modified-release doxycycline capsules once daily for papulopustular rosacea monotherapy results from a large community-based trial in subgroups based on gender. J Drugs Dermatol. 2012;11:703–7. PubMed
12.
Zurück zum Zitat Johnson SM, LeVine P. Self-reported treatment impressions and satisfaction of papulopustular rosacea patients treated with doxycycline, USP, 40 mg capsules. J Drugs Dermatol. 2011;10:1376–81. PubMed Johnson SM, LeVine P. Self-reported treatment impressions and satisfaction of papulopustular rosacea patients treated with doxycycline, USP, 40 mg capsules. J Drugs Dermatol. 2011;10:1376–81. PubMed
13.
Zurück zum Zitat Webster GF. An open-label, community-based, 12-week assessment of the effectiveness and safety of monotherapy with doxycycline 40 mg (30-mg immediate-release and 10-mg delayed-release beads). Cutis. 2010;86(5 Suppl.):7–15. PubMed Webster GF. An open-label, community-based, 12-week assessment of the effectiveness and safety of monotherapy with doxycycline 40 mg (30-mg immediate-release and 10-mg delayed-release beads). Cutis. 2010;86(5 Suppl.):7–15. PubMed
14.
Zurück zum Zitat Wollina U, Verma SB. Rosacea and rhinophyma: not curse of the Celts but Indo Eurasians. J Cosmet Dermatol. 2009;8:234–5. CrossRefPubMed Wollina U, Verma SB. Rosacea and rhinophyma: not curse of the Celts but Indo Eurasians. J Cosmet Dermatol. 2009;8:234–5. CrossRefPubMed
15.
Zurück zum Zitat Alexis AF, Webster G, Preston NJ, Caveney SW, Gottschalk RW. Effectiveness and safety of once-daily doxycycline capsules as monotherapy in patients with rosacea: an analysis by Fitzpatrick skin type. J Drugs Dermatol. 2012;11:1219–22. PubMed Alexis AF, Webster G, Preston NJ, Caveney SW, Gottschalk RW. Effectiveness and safety of once-daily doxycycline capsules as monotherapy in patients with rosacea: an analysis by Fitzpatrick skin type. J Drugs Dermatol. 2012;11:1219–22. PubMed
16.
Zurück zum Zitat Baldwin HE. A community-based study of the effectiveness of doxycycline 40 mg (30-mg immediate-release and 10-mg delayed-release beads) on quality of life and satisfaction with treatment in participants with rosacea. Cutis. 2010;86(5 Suppl.):26–36. PubMed Baldwin HE. A community-based study of the effectiveness of doxycycline 40 mg (30-mg immediate-release and 10-mg delayed-release beads) on quality of life and satisfaction with treatment in participants with rosacea. Cutis. 2010;86(5 Suppl.):26–36. PubMed
17.
Zurück zum Zitat Fowler JF Jr. Combined effect of anti-inflammatory dose doxycycline (40-mg doxycycline, usp monohydrate controlled-release capsules) and metronidazole topical gel 1 % in the treatment of rosacea. J Drugs Dermatol. 2007;6:641–5. PubMed Fowler JF Jr. Combined effect of anti-inflammatory dose doxycycline (40-mg doxycycline, usp monohydrate controlled-release capsules) and metronidazole topical gel 1 % in the treatment of rosacea. J Drugs Dermatol. 2007;6:641–5. PubMed
18.
Zurück zum Zitat Del Rosso JQ, Bruce S, Jarratt M, Menter A, Staedtler G. Efficacy of topical azelaic acid (AzA) gel 15 % plus oral doxycycline 40 mg versus metronidazole gel 1 % plus oral doxycycline 40 mg in mild-to-moderate papulopustular rosacea. J Drugs Dermatol. 2010;9:607–13. PubMed Del Rosso JQ, Bruce S, Jarratt M, Menter A, Staedtler G. Efficacy of topical azelaic acid (AzA) gel 15 % plus oral doxycycline 40 mg versus metronidazole gel 1 % plus oral doxycycline 40 mg in mild-to-moderate papulopustular rosacea. J Drugs Dermatol. 2010;9:607–13. PubMed
19.
Zurück zum Zitat Fender AB, Ignatovich Y, Mercurio MG. Pyoderma faciale. Cutis. 2008;81:488–90. PubMed Fender AB, Ignatovich Y, Mercurio MG. Pyoderma faciale. Cutis. 2008;81:488–90. PubMed
20.
Zurück zum Zitat Smith LA, Meehan SA, Cohen DE. Rosacea fulminans with extrafacial lesions in an elderly man: successful treatment with subantimicrobial-dose doxycycline. J Drugs Dermatol. 2014;13:763–5. PubMed Smith LA, Meehan SA, Cohen DE. Rosacea fulminans with extrafacial lesions in an elderly man: successful treatment with subantimicrobial-dose doxycycline. J Drugs Dermatol. 2014;13:763–5. PubMed
21.
Zurück zum Zitat Pfeffer I, Borelli C, Zierhut M, Schaller M. Treatment of ocular rosacea with 40 mg doxycycline in a slow release form. J Dtsch Dermatol Ges. 2011;9:904–7. PubMed Pfeffer I, Borelli C, Zierhut M, Schaller M. Treatment of ocular rosacea with 40 mg doxycycline in a slow release form. J Dtsch Dermatol Ges. 2011;9:904–7. PubMed
22.
Zurück zum Zitat Sobolewska B, Doycheva D, Deuter C, Pfeffer I, Schaller M, Zierhut M. Treatment of ocular rosacea with once-daily low-dose doxycycline. Cornea. 2014;33:257–60. PubMed Sobolewska B, Doycheva D, Deuter C, Pfeffer I, Schaller M, Zierhut M. Treatment of ocular rosacea with once-daily low-dose doxycycline. Cornea. 2014;33:257–60. PubMed
23.
Zurück zum Zitat Thestrup-Pedersen K, Hjorth N. Red scalp: a previously undescribed disease of the scalp? Ugeskr Laeger. 1987;149:2141–2. PubMed Thestrup-Pedersen K, Hjorth N. Red scalp: a previously undescribed disease of the scalp? Ugeskr Laeger. 1987;149:2141–2. PubMed
24.
Zurück zum Zitat Oberholzer PA, Nobbe S, Kolm I, Kerl K, Kamarachev J, Trüeb RM. Red scalp disease—a rosacea-like dermatosis of the scalp? Successful therapy with oral tetracycline. Dermatology. 2009;219:179–81. CrossRefPubMed Oberholzer PA, Nobbe S, Kolm I, Kerl K, Kamarachev J, Trüeb RM. Red scalp disease—a rosacea-like dermatosis of the scalp? Successful therapy with oral tetracycline. Dermatology. 2009;219:179–81. CrossRefPubMed
25.
Zurück zum Zitat Macdonald JB, Macdonald B, Golitz LE, LoRusso P, Sekulic A. Cutaneous adverse effects of targeted therapies: part I: inhibitors of the cellular membrane. J Am Acad Dermatol. 2015;72:203–18. CrossRefPubMed Macdonald JB, Macdonald B, Golitz LE, LoRusso P, Sekulic A. Cutaneous adverse effects of targeted therapies: part I: inhibitors of the cellular membrane. J Am Acad Dermatol. 2015;72:203–18. CrossRefPubMed
26.
Zurück zum Zitat Macdonald JB, Macdonald B, Golitz LE, LoRusso P, Sekulic A. Cutaneous adverse effects of targeted therapies: part II: inhibitors of intracellular molecular signaling pathways. J Am Acad Dermatol. 2015;72:221–36. CrossRefPubMed Macdonald JB, Macdonald B, Golitz LE, LoRusso P, Sekulic A. Cutaneous adverse effects of targeted therapies: part II: inhibitors of intracellular molecular signaling pathways. J Am Acad Dermatol. 2015;72:221–36. CrossRefPubMed
27.
Zurück zum Zitat Sanlorenzo M, Choudhry A, Vujic I, et al. Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma. J Am Acad Dermatol. 2014;71:1102–9. PubMedCentralCrossRefPubMed Sanlorenzo M, Choudhry A, Vujic I, et al. Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma. J Am Acad Dermatol. 2014;71:1102–9. PubMedCentralCrossRefPubMed
28.
Zurück zum Zitat Sibaud V, Tournier E, Roché H, Del Giudice P, Delord JP, Hubiche T. Late epidermal growth factor receptor inhibitor-related papulopustular rash: a distinct clinical entity. Clin Exp Dermatol. 2015. doi: 10.​1111/​ced.​12675. Sibaud V, Tournier E, Roché H, Del Giudice P, Delord JP, Hubiche T. Late epidermal growth factor receptor inhibitor-related papulopustular rash: a distinct clinical entity. Clin Exp Dermatol. 2015. doi: 10.​1111/​ced.​12675.
29.
Zurück zum Zitat Shibata M, Katsuyama M, Onodera T, Ehama R, Hosoi J, Tagami H. Glucocorticoids enhance Toll-like receptor 2 expression in human keratinocytes stimulated with Propionibacterium acnes or proinflammatory cytokines. J Invest Dermatol. 2009;129:375–82. CrossRefPubMed Shibata M, Katsuyama M, Onodera T, Ehama R, Hosoi J, Tagami H. Glucocorticoids enhance Toll-like receptor 2 expression in human keratinocytes stimulated with Propionibacterium acnes or proinflammatory cytokines. J Invest Dermatol. 2009;129:375–82. CrossRefPubMed
30.
Zurück zum Zitat Vaubel J, Livingstone E, Schadendorf D, Zimmer L. Retarded low-dose doxycycline for EGFR or MEK inhibitor-induced papulopustular rash. J Eur Acad Dermatol Venereol. 2014;28:1685–9. CrossRefPubMed Vaubel J, Livingstone E, Schadendorf D, Zimmer L. Retarded low-dose doxycycline for EGFR or MEK inhibitor-induced papulopustular rash. J Eur Acad Dermatol Venereol. 2014;28:1685–9. CrossRefPubMed
31.
Zurück zum Zitat Rathi SK, Kumrah L. Topical corticosteroid-induced rosacea-like dermatitis: a clinical study of 110 cases. Indian J Dermatol Venereol Leprol. 2011;77:42–6. CrossRefPubMed Rathi SK, Kumrah L. Topical corticosteroid-induced rosacea-like dermatitis: a clinical study of 110 cases. Indian J Dermatol Venereol Leprol. 2011;77:42–6. CrossRefPubMed
32.
Zurück zum Zitat Tempark T, Shwayder TA. Perioral dermatitis: a review of the condition with special attention to treatment options. Am J Clin Dermatol. 2014;15:101–13. CrossRefPubMed Tempark T, Shwayder TA. Perioral dermatitis: a review of the condition with special attention to treatment options. Am J Clin Dermatol. 2014;15:101–13. CrossRefPubMed
33.
Zurück zum Zitat Rosso JQ. Management of papulopustular rosacea and perioral dermatitis with emphasis on iatrogenic causation or exacerbation of inflammatory facial dermatoses: use of doxycycline-modified release 40 mg capsule once daily in combination with properly selected skin care as an effective therapeutic approach. J Clin Aesthet Dermatol. 2011;4:20–30. PubMedCentralPubMed Rosso JQ. Management of papulopustular rosacea and perioral dermatitis with emphasis on iatrogenic causation or exacerbation of inflammatory facial dermatoses: use of doxycycline-modified release 40 mg capsule once daily in combination with properly selected skin care as an effective therapeutic approach. J Clin Aesthet Dermatol. 2011;4:20–30. PubMedCentralPubMed
34.
Zurück zum Zitat van Zuuren EJ, Fedorowicz Z, Carter B, van der Linden MM, Charland L. Interventions for rosacea. Cochrane Database Syst Rev. 2015;4:CD003262. PubMed van Zuuren EJ, Fedorowicz Z, Carter B, van der Linden MM, Charland L. Interventions for rosacea. Cochrane Database Syst Rev. 2015;4:CD003262. PubMed
35.
Zurück zum Zitat Yoo SE, Lee DC, Chang MH. The effect of low-dose doxycycline therapy in chronic meibomian gland dysfunction. Korean J Ophthalmol. 2005;19:258–63. CrossRefPubMed Yoo SE, Lee DC, Chang MH. The effect of low-dose doxycycline therapy in chronic meibomian gland dysfunction. Korean J Ophthalmol. 2005;19:258–63. CrossRefPubMed
Metadaten
Titel
Subantimicrobial-dose doxycycline monohydrate in dermatology
verfasst von
Prof. Dr. Uwe Wollina
Publikationsdatum
01.12.2015
Verlag
Springer Vienna
Erschienen in
Wiener Medizinische Wochenschrift / Ausgabe 23-24/2015
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI
https://doi.org/10.1007/s10354-015-0399-9